Small-Angle X-ray Scattering for Pharmaceutical Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Small-Angle X-ray Scattering for Pharmaceutical Applications
The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.


Pharmaceutical Technology
Volume 34, pp. s32-s37

Applications

SAXS has proven particularly useful in several pharmaceutical applications. This section will describe the most important of them.

Functionalization of self-assembled structures. Self-assembled structures have provoked considerable interest because they can lead to functional materials with nanoscale structures (11–13). SAXS can determine key relationships between nanostructures and their functions.

Scientists often use micelles, self-assemblies of amphiphilic molecules, to solubilize water-insoluble functional substances. Lyotropic liquid crystals in lamellar and reversed-hexagonal phases are used for emulsion-type products. Liposomes or vesicles consisting of phospholipids or synthetic surfactant bilayers play an essential role and act as nanocapsules. Polymer gels are used in various products, including drug carriers.

Pharmaceutical materials. Drug-delivery systems transport drugs to affected parts of the body. Nanocarriers, typically in the size range of 20 to 100 nm, provide the required amount of drugs promptly to a specifically affected part with pinpoint accuracy. Various self-assembly systems (e.g., micelles, microemulsions, liposomes, cubosomes, and polymer-gel nanoparticles) have been tested as drug carriers.

Liquid crystals. Lytropics are important for biological systems. The SAXS method provides structural information about heterogeneities, aggregate ordering, size, shape, separation, and intermolecular spacing within the aggregate stack and helps scientists study the interdependence of morphology and phase behavior. The applications of liquid crystals include biological membranes (e.g., drug-delivery carriers).

Mesoporous materials. Mesoporous materials have pore apertures similar in size to small biological molecules. Mesoporous materials with a narrow pore-size distribution may thus be useful as hosts, supports, catalysts, and separation media for these molecules. The pore-size distribution can be determined with SAXS.

Membranes. The functionality of biological membranes depends on the geometrical and chemical properties of the amphiphilic molecules of the membrane walls. Membrane parameters such as the electron-density profile or flexibility affect the membrane's functionality. Permeability and the tendency to reorganize into micelles, lamellar stacks, or vesicles strongly depend on the internal arrangement of the molecules in the bilayers.

The phospholipid-bilayer membranes can be studied with the SAXS for electron density, thickness, repeat distance of lamellae and stacks, number of layers, packing, and flexibility parameters.

Proteins in solution. Proteins are complex macromolecules. Many diseases are linked to protein misfolding. Structure changes may happen as a function of time, pH, ionic strength, and changes in various solution conditions. SAXS helps identify structural states and changes of biological macromolecules and helps correlate these changes to their biological functions. Over the past decades, 3-D structures of a vast number of biological molecules have been determined using X-ray crystallography and nuclear-magnetic resonance (NMR) (14). However, these high-resolution methods have their own limitations.

Structure determination by X-ray crystallography requires high-quality protein crystals that are complex and costly to produce. NMR allows structures in solution to be studied, but the size of the protein typically accessible by NMR is still much smaller than that of X-ray crystallography.

Some SAXS instruments allow simultaneous measurements of small and wide-angle X-ray scattering from proteins in solution. SAXS successfully determines the ternary and quaternary structures by investigating the overall size and shape. The technique has achieved considerable success in restoring 3-D structures of proteins from the scattering patterns. Experimental setups with wide simultaneous and continuous q-ranges directly probe distance correlations on length scales that are small compared with the overall protein dimensions. The setups may contain rich information about fine-structure details of proteins in solution (15–18). Scattering data in the higher q region is sensitive to protein conformation states (i.e., secondary structures and their packing) and also enables scattering patterns to be compared quantitatively with calculated patterns from detailed structure models. It can be used as an additional information input for the evaluation of NMR data as well (19, 20).

Protein crystallization. To understand and predict protein crystallization from solutions have been paramount tasks for years. The SAXS method's sensitivity helps it detect aggregate structures at an early stage and therefore allows it to indicate the optimum conditions for the onset of protein crystallization.

Lipoproteins. Several diseases are associated with changes in the concentration of blood lipoproteins. SAXS performs fast and precise measurements of lipoprotein particles using small amounts of sample. Its ability to measure all fractions of lipoproteins simultaneously makes SAXS a cost-effective and convenient method for lipoprotein analysis in scientific studies and medical practices.

Carbohydrates. The SAXS method is useful in investigating native starch, its structure, and changes in the structure. The technique also helps measure lamellar repeat distance, fractional lamellar crystallinity, width of the distribution of lamellar sizes, and the number of semicrystalline repeats within each growth ring.

Conclusion

Small-angle X-ray scattering (SAXS) has emerged as an essential tool for structural analysis at length scales as large as 100 nm. The SAXS method yields information not only on particle size and shape, but also on the internal structure and radial electron density profiles of disordered and partially ordered systems.

In the past, the experimental data only enabled the direct determination of overall particle parameters (e.g., mean radius of gyration, particle symmetry, surface per volume) of the macromolecules. In terms of 3D models, the analysis was limited to simple geometrical bodies (e.g., spherical, cylindrical, lamellar) or combinations of them.

The 1990s brought a breakthrough in SAXS data analysis methods that allowed ab initio shape and domain-structure determination and detailed modeling of macromolecular complexes using rigid body refinement (21–23). In dense systems, the scattered intensity is a combination of single-particle scattering (i.e., form factor) and interparticle scattering (i.e., structure factor). The generalized indirect Fourier transform method, one of the most recent developments in data-evaluation programs, allows the interpretation of such scattering data (24). Information about interparticle interactions in dense systems can be deduced by analyzing the structure factor with various potential models assuming repulsive or attractive interactions. SAXS has become a powerful tool for pharmaceutical and biotechnology applications.

Acknowledgements

The author would like to thank Heimo Schnablegger, product manager of X-ray structure analysis at Anton Paar, for his comments and suggestions.

Gerd Langenbucher is a product manager for Physica rheometers and Anton Paar SAXSess X-ray structure analysis at Anton Paar USA, 10215 Timber Ridge Dr., Ashland, VA 23005, tel. 804.550.1051, ext. 126, fax 804.550.1057,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here